In an interview conducted at the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021, Meral Beksac, MD, a Professor in the Department of Hematology at Ankara University, Ankara, Turkey, discusses response monitoring in patients with multiple myeloma. She highlights the useful tools for prognostic and response monitoring, including urine and serum-free light chain, next-generation sequencing, PET-CT, and measurable residual disease. Dr Beksac also discusses recent clinical trials designed to investigate MRD for response assessment in multiple myeloma.